dc.contributor.author
Kretzler, Lucie
dc.contributor.author
Mues, Christoph
dc.contributor.author
Wunderlich, Carsten
dc.contributor.author
Langbein, Anke
dc.contributor.author
Spitzer, S. G.
dc.contributor.author
Gerk, Ulrich
dc.contributor.author
Schellong, Sebastian
dc.contributor.author
Ketteler, Thomas
dc.contributor.author
Neuser, Hans
dc.contributor.author
Schwefer, Marcus
dc.contributor.author
Strasser, Ruth
dc.contributor.author
Ibrahim, Karim
dc.contributor.author
Schoen, Steffen
dc.contributor.author
Christoph, Marian
dc.date.accessioned
2023-11-22T11:32:59Z
dc.date.available
2023-11-22T11:32:59Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/41590
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-41310
dc.description.abstract
Background: Various randomized multicenter studies have shown that percutaneous left atrial appendage closure (LAAC) is not inferior in stroke prevention compared to vitamin K antagonists (VKA) and can be performed safely and effectively.
Aims: The prospective multicenter ORIGINAL registry in the Free State of Saxony (saxOnian RegIstry analyzinG and followINg left atrial Appendage cLosure) investigated the efficiency and safety of LAAC with Watchman or Amulet device in a real word setting. A special focus was put on the influence of LAAC frequency on periprocedural efficiency and safety.
Methods and results: The total of 482 consecutive patients (Abbott Amulet N = 93 and Boston Scientific Watchman N = 389) were included in the periinterventional analyses. After 6 weeks, 353 patients completed the first follow-up including transoesophageal echocardiography (TEE) (73.2%). Successful LAAC could be performed in more than 94%. The complication rate does not significantly differ between device types (p = 0.92) according to Fischer test and comprised 2.2% in the Amulet and 2.3% in the Watchman group. The kind of device and the frequency of LAAC per study center had no influence on the success and complication rates. Device related thrombus could be revealed more frequently in the Watchman group (4.5%) than in the Amulet group (1.4%) but this difference is still not significant in Fisher test (p = 0.14). Same conclusion can be made about residual leakage 1.1% versus 0% [not significant in Fisher test (p = 0.26)]. Dual antiplatelet therapy followed the intervention in 64% and 22% of patients were discharged under a combination of an anticoagulant (VKA/DOAC/Heparin) and one antiplatelet agent.
Conclusions: The ORIGINAL registry supports the thesis from large, randomized trials that LAAC can be performed with a very high procedural success rate in the everyday clinical routine irrespective of the used LAA device (Watchman or Amulet). The postprocedural antithrombotic strategy differs widely among the participating centers.
en
dc.rights.uri
https://creativecommons.org/licenses/by/4.0/
dc.subject
Left atrial appendage
en
dc.subject
Atrial fibrillation
en
dc.subject
Stroke prevention
en
dc.subject
Patient registry
en
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
dc.title
Short term outcome after left atrial appendage occlusion with the AMPLATZER Amulet and WATCHMAN device: results from the ORIGINAL registry (saxOnian RegIstry analyzinG and followINg left atrial Appendage cLosure)
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.articlenumber
271
dcterms.bibliographicCitation.doi
10.1186/s12872-022-02708-4
dcterms.bibliographicCitation.journaltitle
BMC Cardiovascular Disorders
dcterms.bibliographicCitation.number
1
dcterms.bibliographicCitation.originalpublishername
Springer Nature
dcterms.bibliographicCitation.volume
22
refubium.affiliation
Charité - Universitätsmedizin Berlin
refubium.funding
Springer Nature DEAL
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.bibliographicCitation.pmid
35710343
dcterms.isPartOf.eissn
1471-2261